Rituximab identified as an independent risk factor for severe PJP: A case-control study.

Anat ZalmanovichRonen Ben-AmiGalia RahavDanny AlonAllon MosesKaren Olshtain-PopsMiriam WeinbergerPnina ShitritMichal KatzirBat-Sheva GottesmanMichal Chowers

Published in: PloS one (2020)

In conclusion, rituximab, which is prescribed for a wide variety of malignant and inflammatory disorders, was found to be significant risk-factor for PJP. Increased awareness of possible PJP infection in this patient population is warranted.

Keyphrases

diffuse large b cell lymphoma
chronic lymphocytic leukemia
hodgkin lymphoma
case report
oxidative stress
early onset
drug induced